| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 673.1 | 7.9 |
| Profit before tax | 563.4 | -86.4 |
| Net income | 549.8 | -86.4 |
| EPS (diluted, $ a share) | $4.73 | $-1.03 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +8426.3% |
|---|---|
| Operating margin | 83.1% |
10-Q filed with the SEC, NASDAQ: NRIX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Nurix Therapeutics, Inc.: key numbers
- Share price
- $14.73Close, Nov 16
- Market cap
- $1.61B
- Shares outstanding
- 109.25MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Nurix Therapeutics, Inc.
All →Nurix Therapeutics CFO Houte Hans van Sells $74.6K of Stock
Houte Hans van, CFO, sold 4,769 shares of Nurix Therapeutics, Inc. at $15.38 to $16.20 a share (average $15.63) in 2 transactions, worth $74.6K in total on Nov 4, 2026. Shares held after the trade: 42,745 (-3.3%).
- Value
- $74.6K
- Shares
- 4,769
- Average price
- $15.63
- Role
- CFO
- Holding change
- -3.3%
- Trade date
- Nov 4, 2026
Nurix Therapeutics CLO Christine Ring Sells $432K of Stock
Christine Ring, CLO, sold 16,715 shares of Nurix Therapeutics, Inc. at $25.74 to $26.76 a share (average $25.84) in 3 transactions, worth $432K in total between Nov 2, 2026 and Nov 3, 2026. Shares held after the trade: 4,406 (-58.1%).
- Value
- $432K
- Shares
- 16,715
- Average price
- $25.84
- Role
- CLO
- Holding change
- -58.1%
- Trade date
- Nov 2, 2026 to Nov 3, 2026
Nurix Therapeutics Deal Termination with Sanofi S.A.
Nurix Therapeutics announced that its collaboration partner Sanofi has decided to discontinue the Phase 1 clinical trial and terminate the SAR448272 oral STAT6 degrader program. As a result, Nurix will no longer be eligible for future development, regulatory, or commercial milestone payments and royalties specifically for this program, though other licensed programs under the Sanofi collaboration remain active.
- Counterparty
- Sanofi S.A.
Nurix Therapeutics CFO Houte Hans van Sells $74.5K of Stock
Houte Hans van, CFO, sold 2,834 shares of Nurix Therapeutics, Inc. at $26.28 a share, worth $74.5K in total on Oct 30, 2026. Shares held after the trade: 47,514 (-5.6%).
- Value
- $74.5K
- Shares
- 2,834
- Price
- $26.28
- Role
- CFO
- Holding change
- -5.6%
- Trade date
- Oct 30, 2026
Nurix Therapeutics CLO Christine Ring Sells $104K of Stock
Christine Ring, CLO, sold 3,957 shares of Nurix Therapeutics, Inc. at $26.28 a share, worth $104K in total on Oct 30, 2026. Shares held after the trade: 15,335 (-20.5%).
- Value
- $104K
- Shares
- 3,957
- Price
- $26.28
- Role
- CLO
- Holding change
- -20.5%
- Trade date
- Oct 30, 2026
Nurix Therapeutics CSO Gwenn Hansen Sells $143K of Stock
Gwenn Hansen, CSO, sold 5,409 shares of Nurix Therapeutics, Inc. at $26.28 to $26.80 a share (average $26.42) in 2 transactions, worth $143K in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 123,452 (-1.2%).
- Value
- $143K
- Shares
- 5,409
- Average price
- $26.42
- Role
- CSO
- Holding change
- -1.2%
- Trade date
- Oct 30, 2026 to Nov 2, 2026